The global market for myocardial infarction is predicted to rise as heart attacks become more common. Over the projection period, an increase in clinical trials for the treatment of castrate-resistant prostate cancer is anticipated to support market growth for myocardial infarctions worldwide. As an illustration, the Phase 2 randomised, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction was completed in May 2021 by Recardio Inc., a clinical-stage life science company focused on regenerative therapies for cardiovascular diseases.
The global Myocardial Infarction Market is estimated to be valued at US$ 1,816.8 Mn in 2021, and is expected to exhibit a CAGR of 5.9 % over the forecast period (2021-2028).
Leading Companies in the Myocardial Infarction Industry:
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products globally from 1887. The company was headquartered in New York, New York. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Bayer AG
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. On October 2022, The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer.
Sanofi S.A.
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions and was founded in 1973. The company is headquartered in Paris, France and is operational in 100 plus countries. Sanofi and Innate Pharma SA announced in December, 2022 an expansion of their collaboration, with Sanofi licensing a natural killer (NK) cell engager program targeting B7H3 from Innate’s ANKET (Antibody-based NK Cell Engager Therapeutics) platform.